je.st
news
New Adaptive Phase 3 Trial Planned for Gencaro In Atrial Fibrillation
2013-01-29 18:00:00| drugdiscoveryonline News Articles
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases, recently provided an update on a proposed, genetically-targeted clinical trial in atrial fibrillation (“AF”) of the Company’s lead developmental drug, Gencaro (bucindolol hydrochloride)
Tags: trial
phase
planned
adaptive
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||